A randomized phase 2 clinical trial of docetaxel with or without PF-3512676 [agatolimod] as first-line treatment of patients with advanced breast cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 May 2015
At a glance
- Drugs Agatolimod (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Nov 2007 Status changed from in progress to withdrawn prior to recruitment.
- 28 Aug 2007 Status changed from initiated to in progress.
- 18 Jul 2007 New trial record.